News
FDA to quickly review Roche's chemo-free lung cancer regimen
Roche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the FDA agreed to a fast review of Tecentriq monotherapy, preventing the n
